Seikagaku Corporation
572.00
JPY
0.00
(0.00%)
Seikagaku Corporation
TSE:4548
(Tokyo Stock Exchange)
Recent
price
572.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.- Similar Companies
- Business
- Seikagaku Corporation operates as a pharmaceutical and medical device company specializing in the production and sale of glycoconjugates, primarily glycosaminoglycans (GAG) such as hyaluronic acid, and enzymes acting on GAG. The company's core products include joint function improving agents like ARTZ Dispo (purified sodium hyaluronate) and JOYCLU (diclofenac etalhyaluronate sodium); ophthalmic surgery aids such as OPEGAN series (purified sodium hyaluronate) and SHELLGAN (purified sodium hyaluronate/chondroitin sulfate sodium); treatment agents for lumbar disc herniation including HERNICORE (condoliase); and submucosal injection agents for endoscopic surgery like MucoUp (purified sodium hyaluronate). Seikagaku also produces and supplies bulk raw materials including high-purity hyaluronic acid and chondroitin sulfate used in their product formulations. The company markets these products mainly through strategic partnerships with pharmaceutical and medical device sales companies across Japan, North America, Europe, and Asia, including partners such as Kaken Pharmaceutical, Ono Pharmaceutical, Santen Pharmaceutical, Bioventus, and Boston Scientific Japan. The company operates two main business segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL), which involves manufacturing and selling endotoxin-detecting reagents globally. Founded in 1947 and headquartered in Tokyo, Japan, Seikagaku Corporation has recently expanded its global presence by accelerating overseas business expansion, introducing existing and pipeline products to new markets, and improving product lifecycle management, including transitioning packaging materials from glass to plastic for products like ARTZ. In the fiscal year 2024-25, the company has applied for marketing approval of SI-449, an adhesion barrier medical device in Japan, and advanced the development of SI-614, a therapeutic agent for dry eye, undergoing a Phase III clinical study in the U.S. Despite a slight revenue decline in recent reports, Seikagaku has demonstrated strategic focus on new product launches and pipeline progression, strengthening its product portfolio in the orthopedics, ophthalmology, and endoscopic surgery fields while maintaining partnerships to maximize global market penetration. Seikagaku's business model leverages its glycoscience technologies and longstanding expertise in GAGs to deliver high-quality pharmaceuticals and medical devices for musculoskeletal, ophthalmic, and surgical applications. The company continues to innovate with polymer-based therapeutics and enzyme-based products targeting joint and tissue repair, emphasizing research and development collaboration and regulatory advancement to sustain growth in key geographic markets including Japan, North America, Europe, China, and Taiwan. This comprehensive approach positions Seikagaku Corporation as a specialized pharmaceutical and medical device firm with a distinctive focus on glycosaminoglycan-based products, a broad international footprint through partnerships, and recent strategic moves into new product and market development to maintain competitive positioning in the global healthcare industry.